Compare Harley-Davidson Inc (HOG) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Harley-Davidson Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Harley-Davidson Inc trades at $25.86 (market cap $2.78B), while State Street SPDR S&P Biotech ETF trades at $158.99. The key difference: Harley-Davidson Inc pays a 2.75% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Harley-Davidson Inc nearer its low. Which is the better fit depends on your goals.
| HOG | XBI | |
|---|---|---|
Market Cap | $2.78B | — |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $31.03 | $164.28 |
52-Week Low | $17.19 | $86.92 |
Enterprise Value | $3.19B | — |
Dividend Yield | 2.75% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Harley-Davidson (HOG) trades at $26.10, up 0.35% with a bullish technical signal from moving averages. The company reported mixed Q2 2026 results with an EPS beat ($0.75 vs. $0.645 expected) but revenue challenges, while raising full-year guidance. Valuation appears reasonable with P/E of 14.84 and P/S of 0.72, though profitability metrics show pressure with net margin at 4.78%.
The outlook remains cautiously optimistic with analyst consensus at $26.00 target. Key opportunities include North American sales strength and cost-cutting initiatives, while risks involve raw material costs and competitive pressures. Institutional activity shows mixed signals with recent large purchases and sales.
XBI trades at $159.15, up 0.71% with a bullish technical signal from moving averages. The biotech ETF shows strong momentum with a 17% monthly gain, driven by positive clinical data and M&A activity. Analyst coverage remains limited with a single hold rating, while institutional interest grows with recent $793,000 investment from Bay Colony Advisors.
Outlook remains positive given biotech sector resurgence, though elevated RSI suggests near-term overbought conditions. Key risks include sector volatility and regulatory uncertainty, but AI-driven drug discovery and strong pipeline developments provide growth catalysts for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Harley-Davidson Inc
Harley-Davidson is a global leading manufacturer of heavyweight motorcycles, merchandise, parts, and accessories. It sells custom, cruiser, and touring motorcycles and offers a complete line of Harley-Davidson motorcycle parts, accessories, riding gear, and apparel, as well as merchandise. Harley-Davidson Financial Services provides wholesale financing to dealers and retail financing and insurance brokerage services to customers. Harley has historically captured about half of all heavyweight domestic retail motorcycle registrations, a metric it had ceded in 2020 as it repositioned the business, but a level it is working back toward. In recent years the firm has expanded into the adventure touring market with its Pan America model and into electric with the LiveWire brand.
Read more on HOG →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
